



## MONOGRAPH

# Phenoxymethylpenicillin (penicillin V) Monograph - Paediatric

<b>Scope (Staff):</b>	Medical, Pharmacy, Nursing
<b>Scope (Area):</b>	All Clinical Areas

### Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this [DISCLAIMER](#)

### QUICKLINKS

<a href="#">Dosage/Dosage Adjustments</a>	<a href="#">Administration</a>	<a href="#">Compatibility</a>	<a href="#">Monitoring</a>
---	--------------------------------	-------------------------------	----------------------------

### DRUG CLASS

Penicillin antibiotic.<sup>(1)</sup>

### INDICATIONS AND RESTRICTIONS

- Phenoxymethylpenicillin is indicated for **treatment** of dental infections (in combination with metronidazole), acute rheumatic fever (ARF) (if intolerant of intramuscular [benzathine benzylicillin](#)), and acute pharyngitis or tonsillitis due to *Streptococcus pyogenes* (in moderate / severe cases and or to prevent ARF) and Scarlet fever.<sup>(1-7)</sup> Refer to [The 2020 Australian guideline for prevention, diagnosis and management of ARF and RHD \(3.2 edition\)](#).<sup>(8)</sup>
- Phenoxymethylpenicillin is indicated for **prophylaxis** against infection due to encapsulated organisms in susceptible hosts (e.g. asplenia, post haematopoietic stem cell transplantation) and as secondary prophylaxis for ARF (if intolerant to intramuscular [benzathine benzylicillin](#)).<sup>(1-3, 8)</sup>

#### Oral: Unrestricted (green) antibiotic

This is not a restricted agent. Follow standard ChAMP guidelines where appropriate.

**CONTRAINDICATIONS**

- Hypersensitivity to phenoxyethylpenicillin, any component of the formulation or a history of high-risk allergy to other penicillins.<sup>(1, 3-6)</sup>

**PRECAUTIONS**

- Phenoxyethylpenicillin may be prescribed in selected patients with high-risk allergy to another Beta-lactam sub-class (e.g. some cephalosporins, carbapenems) in discussion with Immunology.<sup>(6)</sup>
- In patients with a previous [low risk reaction](#) to phenoxyethylpenicillin or another penicillin (delayed rash [ $>1$ hr after initial exposure] without mucosal or systemic involvement) the risk of subsequent reaction is low. Re-challenge may be acceptable in discussion with Immunology.<sup>(3, 4, 6)</sup>
- In patients with renal impairment, prolonged high doses may result in electrolyte disturbance or neurotoxicity (e.g. seizures, coma), and may increase risk of neutropenia.<sup>(1, 4)</sup>

**FORMULATIONS**

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- 250 mg tablets and capsules
- 50 mg/mL powder for suspension

Imprest location: [Formulary One](#)

**DOSAGE & DOSAGE ADJUSTMENTS**

**Neonates:** [Refer to Neonatal Medication Protocols](#)

**Treatment**

Indication	Dose
Treatment of acute pharyngitis or tonsillitis due to <i>S. pyogenes</i> (including scarlet fever)	<b>Child <math>\geq</math> 4 weeks – 18 years:</b> 15 mg/kg/dose (to a maximum of 500 mg) 12 hourly for <b>10 days</b> . <sup>(1, 2, 8, 9)</sup>  The full 10 day course is required to eradicate <i>S. pyogenes</i> from the nasopharynx. <sup>(1, 2)</sup>
<b>Note:</b> Antibiotics are <b>not</b> indicated for mild tonsillitis in children not at risk of ARF. <sup>(1, 9)</sup>	
Treatment of ARF (if intolerant of intramuscular <a href="#">benzathine benzylpenicillin</a> )	<b>Child <math>\geq</math> 4 weeks – 18 years:</b> 15 mg/kg/dose (to a maximum of 500 mg) 12 hourly for <b>10 days</b> . <sup>(8, 9)</sup>
Dental infections (severe superficial infections)	<b>Child <math>\geq</math> 4 weeks – 18 years:</b> 12.5 mg/kg/dose (to a maximum of 500 mg) four times a day for <b>5 days</b> in combination with metronidazole. <sup>(1, 7)</sup>

**Prophylaxis**

Indication	Dose
Secondary prophylaxis for ARF	<b>Child <math>\geq</math> 4 weeks – 18 years:</b> 250 mg/dose twice daily for 10 <u>years</u> . <sup>(1, 8, 9)</sup>
<b>Note:</b> <a href="#">IM Benzathine benzylpenicillin</a> is preferred for treatment and prophylaxis of ARF/Rheumatic Heart Disease (RHD) due to improved efficacy and patient compliance. <sup>(1, 8, 9)</sup>	
Prophylaxis in asplenia, sickle cell anaemia, functional hyposplenia, post splenectomy or post Haematopoietic stem cell transplantation (HSCT)	<p><b>Child &lt;1 year old:</b> 62.5 mg/dose twice daily.<sup>(2, 6)</sup></p> <p><b>Child 1- &lt; 5 years old:</b> 125 mg/dose twice daily.<sup>(2, 6)</sup></p> <p><b>Children <math>\geq</math> 5 old:</b> 250mg/dose twice daily.<sup>(2, 6)</sup></p> <p>Note: <a href="#">Amoxicillin</a> is often preferred for this indication as it is administered once daily. Refer to <a href="#">ChAMP Medical Prophylaxis Guideline</a> and <a href="#">Asplenia, Hyposplenia and Complement Deficiency Vaccination and Prophylaxis</a></p>

**Dosing in Overweight and Obese Children:** Dose based on measured body weight.<sup>(10)</sup>

**Renal impairment:**

- No dosage adjustment is required in renal impairment; however, the half-life may be prolonged in significant renal impairment.<sup>(3, 4)</sup>
- The potassium content of the preparation should be considered in patients with severe renal impairment.<sup>(11)</sup>

**Hepatic impairment:**

- There are no specific recommendations for dosage adjustment in patients with hepatic impairment. It appears that no dose adjustment is necessary.<sup>(3, 4)</sup>

**RECONSTITUTION & ADMINISTRATION**

- May be given without regard to food, however absorption may be slightly higher if administered on an empty stomach.<sup>(3, 5)</sup>

**Oral powder for suspension 50mg/mL**

- Reconstitute as per the product information with water as follows: Tap bottle until all the powder flows freely, add the total volume of water for reconstitution and shake vigorously to suspend the powder. Store the reconstituted suspension in a refrigerator between 2°C and 8°C and discard any remaining suspension after 10 days.<sup>(11)</sup>

**MONITORING**

Renal, hepatic and haematological function should be monitored with prolonged, high dose therapy (i.e. treatment doses for longer than 10 days).<sup>(1, 4)</sup>

**ADVERSE EFFECTS**

**Common:** diarrhoea, nausea, immunological reactions (allergy, rash, erythema, urticaria, contact dermatitis, fever, angioedema, bronchospasm, interstitial nephritis, haemolytic anaemia, eosinophilia, serum sickness-like syndrome, exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis).<sup>(1, 6)</sup>

**Infrequent:** vomiting, *Clostridioides difficile* associated disease.<sup>(1, 6)</sup>

**Rare:** black tongue, electrolyte disturbances, neurotoxicity (with high dose e.g. drowsiness, hallucinations, coma, seizures), bleeding, blood dyscrasias (e.g. thrombocytopenia, neutropenia).<sup>(1, 6)</sup>

**STORAGE****50 mg/mL oral powder for suspension:**

- Prior to reconstitution: Store below 25°C.<sup>(11)</sup>
- After reconstitution: Refrigerate (between 2-8°C).<sup>(11)</sup>
- Refer to packaging for storage conditions as this may differ between brands and strengths.

**Tablets and capsules:**

- Store below 25°C (refer to packaging for storage conditions as this may differ between brands and strengths).<sup>(11)</sup>

**INTERACTIONS**

This medication may interact with other medications; consult PCH approved references (e.g. [Clinical Pharmacology](#)), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

*\*\*Please note: The information contained in this guideline is to assist with the preparation and administration of **phenoxyethylpenicillin (penicillin V)**. Any variations to the doses recommended should be clarified with the prescriber prior to administration\*\**

**Related CAHS internal policies, procedures and guidelines**

[Antimicrobial Stewardship Policy](#)

[ChAMP Empiric Guidelines and Monographs](#)

[KEMH Neonatal Medication Protocols](#)


[ChAMP Medical Prophylaxis Guideline](#)

[Asplenia, Hyposplenia and Complement Deficiency Vaccination and Prophylaxis](#)

## References

1. Australian Medicines Handbook. Adelaide, S. Aust.: Australian Medicines Handbook; 2022 [cited 2023 2nd May]. Available from: <https://amhonline-amh-net-au.pklibresources.health.wa.gov.au/>.
2. Antibiotic Writing Group. Therapeutic Guidelines - Antibiotic. West Melbourne: Therapeutic Guidelines Ltd; 2022. Available from: <https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/etgAccess>.
3. Clinical Pharmacology powered by ClinicalKey [Internet]. Elsevier. 2022 [cited 2023 May 29th]. Available from: <http://www.clinicalpharmacology-ip.com.pklibresources.health.wa.gov.au/default.aspx>.
4. Up To Date - Paediatric Drug information [Internet]. Lexicomp. 2022 [cited 2023 May 29th]. Available from: <https://www.uptodate-com.pklibresources.health.wa.gov.au/contents/table-of-contents/drug-information/pediatric-drug-information>.
5. IBM Micromedex [Internet]. Truven Health Analytics. 2022 [cited 2023 May 29th]. Available from: <http://www-micromedexsolutions-com.pklibresources.health.wa.gov.au/micromedex2/librarian>.
6. Paediatric Formulary Committee. BNF for Children: 2022. London: BMJ Group Pharmaceutical Press; 2022.
7. Therapeutic Guidelines - Oral and Dental [Internet]. Therapeutic Guidelines. 2021.
8. RHD Australia (ARF/RHD Writing Group). The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3.2 edition, March 2022): National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand; 2020.
9. Royal Australian College of General Practitioners, Pharmaceutical Society of Australia, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. AMH: Children's Dosing Companion. Adelaide: Australian Medicines Handbook Pty Ltd; 2022.
10. Kendrick JG, Carr RR, Ensom MH. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing. Clin Ther. 2015;37(9):1897-923.
11. MIMS Australia. MIMS online [full product information]. St Leonards, N.S.W: CMP Medica Australia.; 2022 [cited 2023 21st Mar].

This document can be made available in alternative formats on request for a person with a disability.

<b>File Path:</b>	<a href="W:\Paediatrics\PMH\ChAMP\Monographs\FINALISED\00 Current version 00">W:\Paediatrics\PMH\ChAMP\Monographs\FINALISED\00 Current version 00</a>		
<b>Document Owner:</b>	Head of Department – Infectious Diseases		
<b>Reviewer / Team:</b>	Children’s Antimicrobial Management Program Pharmacist		
<b>Date First Issued:</b>	September 2015	<b>Last Reviewed:</b>	May 2023
<b>Amendment Dates:</b>	September 2018, May 2020, May 2023	<b>Next Review Date:</b>	July 2026
<b>Approved by:</b>	Drugs and Therapeutics Committee	<b>Date:</b>	July 2023
<b>Endorsed by:</b>	Chair, Drugs and Therapeutics Committee	<b>Date:</b>	July 2023
<b>Standards Applicable:</b>	NSQHS Standards:  NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled



**Healthy kids, healthy communities**

Compassion Excellence Collaboration Accountability Equity Respect

Neonatology | Community Health | Mental Health | Perth Children’s Hospital